Researchers will present the results of two late-stage studies on Johnson & Johnson (JNJ) and Pfizer Inc. (PFE)’s experimental drug for Alzheimer’s disease, bapineuzumab, at the American Neurological Association meeting in early October.
The findings of the two studies will be presented in Boston on Oct. 8 in a session dedicated to immune-based treatments for neurological disorders, according to the meeting program posted on the neurological association’s website. The results, if positive, could lead the companies to file for U.S. Food and Drug Administration approval of the medicine.
To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at email@example.com
To contact the editor responsible for this story: Reg Gale at firstname.lastname@example.org